As part of the DPA, Taro U.S.A. has agreed to cooperate fully with the ongoing criminal investigations of the Cartel Department. As part of the agreement, the parties will make a joint request, subject to the Tribunal`s agreement, to defer the prosecution and trial of the accused for the duration of the CCA. In June 2020, the DOJ accused Glenmark Pharmaceuticals, Inc., of cashing in $200 million in surcharges for pravastatin and other drugs through illegal deals with competing generic pharmaceutical companies. Glenmark accepted no fault and pledged to fight the charges. The Cartel Department also announced a Deferred Prosecution Agreement (DPA) to resolve the charges against Taro U.S.A. in which the company admitted that its sales targeted by the incriminated conspiracies had exceeded US$500 million. According to the prosecution and the DPA, Taro U.S.A. and its co-conspirators agreed to set prices, award customers, and manipulate offers for many generic drugs, including drugs to prevent and control seizures and treat bipolar disorder, pain and arthritis, as well as various skin diseases. Taro, Aprahamian and others are accused of conspiring with Sandoz from March 2013 to December 2015 to set prices, assign customers and manipulate offers for numerous generic drugs. Sandoz is a department of Novartis that has certainly had enough of the DOJ`s lawsuits – most recently because of LARPA, False Claims Act and anti-kickback. As part of a three-year agreement on deferred prosecutions, Taro will pay $205.7 million and agree to cooperate in the ministry`s ongoing investigation, the Justice Department said. In connection with the filing, the DOJ announced a Deferred Prosecution Agreement (DPA) shedding light on the charges against Taro and in which Taro agreed to pay $205,653,218 in criminal penalties and admitted that the sales targeted by the incriminated conspiracies exceeded US$500 million.
The DOJ Antitrust Division`s multi-year antitrust investigation into the generic pharmaceutical industry is accelerating. The most recent company to reach an agreement is Taro Pharmaceuticals, which has agreed to enter into a deferred prosecution agreement and pay a $205.7 million fine to clarify allegations related to a criminal price cartel. The transaction between the antitrust department and Taro is the 10th case and the 6th company accused or prosecuted. “The charges filed today in the U.S. District Court for the Eastern District of Pennsylvania are indicative of my office`s ongoing efforts to investigate and indict companies and executives who set generic drug prices,” said U.S. Attorney McSwain. “We and our partners in the antitrust division and other federal law enforcement agencies continue to focus heavily on cartels on the illegal pricing and allocation of generic drugs. These charges and the resulting agreement on deferred prosecutions, subject to the approval of the Tribunal, are another significant achievement in this area. In the Deferred Prosecution Agreement, Taro U.S.A. . .